Answers are grounded in this paper and cite their sources.
Background: Automated insulin delivery (AID) improves glycemic outcomes in trials, but long-term real-world data on comprehensive continuous glucose monitoring (CGM) metrics remain limited in the Middle East. Methods: We conducted a prospective observational cohort study of adults with type 1 diabetes mellitus (T1DM) initiating Control-IQ (CIQ) or MiniMed 780G (MMG) at King Fahad Medical City, Riyadh, Saudi Arabia, between December 2023 and November 2025. Participants were followed for 12 months. Continuous glucose monitoring outcomes included time in range (TIR: 70-180 mg/dL), time above range (TAR), time below range (TBR), glycemic management indicator (GMI), mean sensor glucose, and coefficient of variation (CV) and assessed at baseline and 6 post-initiation time points. Glycated hemoglobin A1c (HbA1c) was assessed using paired pre- and post-AID values. Results: A total of 132 adults were included: 76 using CIQ and 56 using MMG. Mean age was 27.2 ± 7.7 years, 68.9% were female, and mean diabetes duration was 14.5 ± 7.9 years. Time in range increased from 59.0 ± 15.4% at baseline to 72.3 ± 10.2% at 2 weeks and remained sustained at 12 months (73.5 ± 11.5%; +15.1 percentage points; P < .001). Time below range <70 mg/dL decreased from 5.3 ± 5.3 to 1.4 ± 1.2%. Glycated hemoglobin A1c decreased from 7.42 ± 1.13 to 6.52 ± 0.73% ( P < .001; n = 106). Time in range ≥70% increased from 29.0% to 71.0%, and HbA1c <7% increased from 30.3% to 74.5%. Severe hypoglycemia and diabetic ketoacidosis rates were significantly reduced. Conclusion: In a Saudi tertiary diabetes center, AID initiation was associated with rapid and sustained 12-month improvements in TIR, HbA1c, hypoglycemia exposure, and acute diabetes-related events.
No takes yet. Share an insight, caveat, or question.
Alqahtani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: